Nanexa AB Logo

Nanexa AB

Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.

NANEXA | ST

Overview

Corporate Details

ISIN(s):
SE0007074166 (+2 more)
LEI:
549300J5L2ECZTLID491
Country:
Sweden
Address:
Virdings Allé 2, 754 50 Uppsala
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanexa AB is a pharmaceutical company that develops long-acting injectable drugs using its proprietary PharmaShell® drug delivery system. The technology is based on Atomic Layer Deposition (ALD), a precision nanotechnology used to coat drug particles, enabling high drug loads and precisely controlled, extended-release formulations. This aims to improve treatment efficacy and patient convenience by reducing dosing frequency. The company advances its own product pipeline, including a long-acting GLP-1 formulation for type 2 diabetes (NEX-22), and also engages in collaborative projects with other pharmaceutical firms to apply its technology to their drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nanexa AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanexa AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanexa AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160

Talk to a Data Expert

Have a question? We'll get back to you promptly.